SCHEMBL15968784

SCHEMBL15968784

O=C(O)c1ccc(OCC2CC2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
RAB9A P51151 1/20 0.55
NR1H4 Q96RI1 2/20 0.48
KDM4C Q9H3R0 3/20 0.47
RBP4 P02753 1/20 0.47
TTR P02766 1/20 0.47
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
MAP4K4 O95819 1/20 0.47
FFAR1 O14842 2/20 0.46
PPARD Q03181 2/20 0.46
FFAR4 Q5NUL3 1/20 0.46
PARP15 Q460N3 1/20 0.45
PARP10 Q53GL7 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
KDM5A P29375 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10148081 0.94 MAP4K4 (0.54) LMNAMAPK1HTTRAB9ANR1H4
SCHEMBL24968528 0.89 KDM4C (0.53) LMNAMAPK1HTTRAB9AKDM4C
SCHEMBL662159 0.88 TTR (0.50) LMNAMAPK1HTTRAB9ANR1H4
SCHEMBL15968595 0.87 PDE4B (0.46) PDE4APDE4BPDE4CPDE4DFFAR1
SCHEMBL20463367 0.87 SLC6A9 (0.53) LMNAMAPK1HTTRAB9APDE4A
SCHEMBL28034346 0.86 PDE4B (0.53) NR1H4PDE4APDE4BPDE4CPDE4D
SCHEMBL1750562 0.85 LMNA (0.53) LMNAMAPK1HTTRAB9AFFAR4
SCHEMBL1861841 0.84 PDE4B (0.50) LMNAMAPK1HTTRAB9APDE4A
SCHEMBL22386754 0.83 PDE4B (0.46) PDE4APDE4BPDE4CPDE4DFFAR1
SCHEMBL10148083 0.82 MAP4K4 (0.54) NR1H4KDM4CRBP4TTRPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
EP-2772485-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-09-03 EP disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed
CN-103998432-A Bicyclic compounds TAKEDA PHARMACEUTICAL 2014-08-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 LMNA 2745/4885MAPK1 1089/4885HTT 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.